Press Releases

Press Releases

Date	Title	View
June 4, 2026	AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
May 21, 2026	AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
May 11, 2026	AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
May 7, 2026	AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
March 31, 2026	AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
March 17, 2026	AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
March 9, 2026	AN2 Therapeutics Announces $40 Million Private Placement Financing
March 3, 2026	AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
February 17, 2026	AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
January 12, 2026	AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

Investors